The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BSE has received a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, filed by HDFC Mutual Fund in relation to Piramal Pharma Ltd. This regulation requires entities to report when their shareholding crosses prescribed thresholds (typically in 5% increments or changes of 2% or more for those already holding above 5%). The filing itself does not specify whether the mutual fund increased or reduced its stake, nor does it mention the exact percentage held or the change in quantity. HDFC Mutual Fund, as a large domestic institutional investor, routinely makes such disclosures across multiple stocks in its portfolio.
For retail investors, this is a routine regulatory disclosure rather than a major corporate event. Without details on the direction (buy or sell) and size of the change, the immediate impact on the stock is unclear. Investors should check the full disclosure on the BSE/NSE portal to understand whether this represents fresh buying, a partial exit, or a passive rebalancing of the fund's holdings.